BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances
Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December
Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23
Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data
Kura Oncology's CEO gives an update on Q3 earnings day
The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem
A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics
Brushing up on the science of obesity with Rhythm Pharmaceuticals’ CEO
Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors
Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy
The CEO of eGenesis elaborates on today's Nature paper using pig kidneys for transplantation in NHPs
The Head of Bayer in the US on pharma and a new $250M cell Tx facility in Berkeley, CA. #HLTH2023
Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023
Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023
Harbinger Health’s Steve Hahn on the science of early cancer Dx after raising a $140M Series B
Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal
Rome Therapeutics’ CEO on the science of the 'Dark Genome' and last week’s $72M Series B extension
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development
Moderna’s Head of R&D explains how mRNA is being tested with other emerging cancer modalities
Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
.png){kind=logo}
